Cargando…
Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date
Glyburide (also known as glibenclamide) is a second-generation sulfonylurea drug that inhibits sulfonylurea receptor 1 (Sur1) at nanomolar concentrations. Long used to target K(ATP) (Sur1–Kir6.2) channels for the treatment of diabetes mellitus type 2, glyburide was recently repurposed to target Sur1...
Autores principales: | King, Zachary A, Sheth, Kevin N, Kimberly, W Taylor, Simard, J Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101021/ https://www.ncbi.nlm.nih.gov/pubmed/30147301 http://dx.doi.org/10.2147/DDDT.S150043 |
Ejemplares similares
-
Medical management of cerebral edema in large hemispheric infarcts
por: DeHoff, Grace, et al.
Publicado: (2022) -
Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles
por: Deng, Gang, et al.
Publicado: (2019) -
Magnetic Resonance Imaging Pilot Study of Intravenous Glyburide in Traumatic Brain Injury
por: Eisenberg, Howard M., et al.
Publicado: (2020) -
Iodine-based dual-energy CT predicts early neurological decline from cerebral edema after large hemispheric infarction
por: Zimmerman, William Denney, et al.
Publicado: (2023) -
A web based dynamic MANA Nomogram for predicting the malignant cerebral edema in patients with large hemispheric infarction
por: Sun, Wenzhe, et al.
Publicado: (2020)